Quantcast

Latest Pneumococcal conjugate vaccine Stories

2010-03-04 08:27:47

A clinical trial of a vaccine against a major cause of pneumonia and meningitis has shown that it can prevent three out of four cases of re-infection in HIV-infected adults in Africa. The trials, conducted in Malawi and funded by the Wellcome Trust, studied the efficacy of a vaccine against infection with the Streptococcus pneumoniae bacteria. These bacteria are a primary cause of pneumonia and when they invade the blood stream and brain "“ so called invasive pneumococcal disease (IPD)...

2010-02-24 10:14:00

Successor to Prevnar is intended for infants, young children SILVER SPRING, Md., Feb. 24 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. Prevnar 13 will be the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in 2000 to prevent invasive pneumococcal disease (IPD) and otitis media. The new vaccine extends the...

2010-02-23 09:10:30

The pneumococcal vaccine for infants and children introduced in 2000 caused a precipitous drop in infections until 2005, when serious illnesses began to rise again, especially infections caused by a strain of the pneumococcal bacteria called 19A, said researchers from Baylor College of Medicine and Texas Children's Hospital in a report in the current issue of the journal Pediatrics. "Of the serotypes (or variants) of Streptococcus pneumoniae (the bacteria that cause pneumococcal disease) now...

2010-02-01 12:10:00

PATH supports FDA advancement of a key step in vaccine development SILVER SPRING, Md., Feb. 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced a collaboration with PATH to advance development of a vaccine to protect children against diseases caused by Streptococcus pneumoniae (pneumococcus), especially pneumonia. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Worldwide, the bacterium also causes infections of the brain (meningitis),...

786402aad589ab0f910a1575eaa0b80d
2009-11-02 12:20:00

On Monday, the UN released an outlined plan that would cost $39 billion to save 5.3 million children from dying of pneumonia worldwide. "Pneumonia is the leading cause of under age five mortality, killing more than 4,000 children every day," said Ann M. Veneman, UNICEF Executive Director. "Effective interventions to reduce deaths caused by pneumonia must be used more widely and made more readily available for children at risk." About 1.8 million children under the age of five die from...

2009-11-02 07:00:00

PHILADELPHIA, Nov. 2 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), presented Safety of a Quadrivalent (A,C,Y,W-135) Meningococcal Vaccine When Given to Infants with Other Pediatric Vaccines at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) this past weekend. The annual meeting of physicians, scientists, and other health-care professionals who specialize in infectious diseases was held from October...

2009-10-19 13:44:40

Use of vaccines can save the lives of millions of children A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths. The findings were based on a systematic review of the results of 6 randomized and controlled trials conducted in the US, Africa, Philippines, and Finland. Eighty percent of children were less likely to...

2009-09-30 14:23:27

Many people who have died of H1N1 influenza in the United States had other bacterial infections that likely contributed to their deaths, health officials say. A report published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report says those who died of H1N1 influenza had co-infections with a common bacteria such as Streptococcus pneumoniae or pneumococcus. The CDC report included an analysis of specimens taken from 77 fatal cases of H1N1. Bacterial...

2009-09-25 10:08:00

COLLEGEVILLE, Pa., Sept. 25 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the company's pneumococcal conjugate vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent Adsorbed]). The CHMP recommends approval of Prevenar 13 for active immunization of children aged 6 weeks to 5 years for...

2009-09-22 10:33:00

NEW YORK, Sept. 22 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry http://www.reportlinker.com/p0120962/Vaccines-2009-World-Market-Analysis-Key-Players-and-Critical-Trends-in-a-Fast-Changing-Industry.html The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related